Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

HEcoPerMed: Health Economic Models for Personalised Medicine

  • Genomics and economics

HEcoPerMed (Health Economic Models for Personalised Medicine) is an EU‑funded project that ran from January 2019 to the end of June 2022. The project responded to the demand for economic models that evaluate personalised medicine treatments. HEcoPerMed also aimed to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of personalised medicine.

Work package three of the project was led by the University of Oxford and focused on financing and payment models that stimulate the integration of personalised medicine across different sectors.

The outputs of the project include a Special Issue published in the Journal of Personalized Medicine, a Position Paper on the lessons learned from the project and future opportunities for personalised medicine, as well as highly cited guidance for the economic evaluation of personalised medicine and a review outlining financing and reimbursement models for personalised medicine.

Funder: Horizon EU 

See project website for more.

External supervisor

Apostolos Tsiachristas, Associate Professor in Health Economics

Apostolos Tsiachristas

Associate Professor in Health Economics

Selected publications

Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems.

Journal article

Koleva-Kolarova R. et al, (2023), Per Med, 20, 357 - 374

Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.

Journal article

Koleva-Kolarova R. et al, (2023), Per Med, 20, 339 - 355

Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries.

Journal article

Szilberhorn L. et al, (2023), Per Med, 20, 387 - 399

Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation.

Journal article

Koleva-Kolarova R. et al, (2023), Per Med, 20, 305 - 319

Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.

Journal article

Kovács G. et al, (2023), Per Med, 20, 375 - 385

Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.

Journal article

Huygens S. et al, (2023), Value Health, 26, 193 - 203

Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients.

Journal article

Tsiachristas A. et al, (2022), BMC Cancer, 22

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Journal article

Koleva-Kolarova R. et al, (2022), Appl Health Econ Health Policy, 20, 501 - 524

The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis.

Journal article

Vellekoop H. et al, (2022), Value Health, 25, 1428 - 1438